PFA
GILD icon

Pathway Financial Advisors’s Gilead Sciences GILD Stock Holding History

Pathway Financial Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-24
Closed -$2K – 440
2017
Q4 		$2K Buy
+24
New +$1.82K ﹤0.01% 432

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pathway Financial Advisors's GILD Position: Q1 2018 in Review

Pathway Financial Advisors sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 24 shares — an estimated $2K sold.

Pathway Financial Advisors first reported a position in GILD in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 1,563 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

  • Pathway Financial Advisors reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
  • Pathway Financial Advisors sold 24 Gilead Sciences shares in Q1 2018, an estimated $2K.
  • Pathway Financial Advisors first reported a position in Gilead Sciences in Q4 2017 and held it in 1 quarter.
  • Pathway Financial Advisors's Gilead Sciences position peaked at $2K in Q4 2017.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on Pathway Financial Advisors's 13F filing for Q1 2018, filed 4 May 2018.